234 related articles for article (PubMed ID: 29943691)
1. ILUVIEN
Habib MS
Ther Deliv; 2018 Aug; 9(8):547-556. PubMed ID: 29943691
[TBL] [Abstract][Full Text] [Related]
2. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Soubrane G; Behar-Cohen F
J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
[TBL] [Abstract][Full Text] [Related]
3. Fluocinolone acetonide for the treatment of diabetic macular edema.
Veritti D; Sarao V; Diplotti L; Samassa F; Lanzetta P
Expert Opin Pharmacother; 2017 Oct; 18(14):1507-1516. PubMed ID: 28764565
[TBL] [Abstract][Full Text] [Related]
4. Fluocinolone acetonide implantable device for diabetic retinopathy.
Schwartz SG; Flynn HW
Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
Massa H; Nagar AM; Vergados A; Dadoukis P; Patra S; Panos GD
J Int Med Res; 2019 Jan; 47(1):31-43. PubMed ID: 30556449
[TBL] [Abstract][Full Text] [Related]
6. A Nonrandomized, Open-Label, Multicenter, Phase 4 Pilot Study on the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (RESPOND).
Figueira J; Henriques J; Amaro M; Rosas V; Alves D; Cunha-Vaz J
Ophthalmic Res; 2017; 57(3):166-172. PubMed ID: 28178701
[TBL] [Abstract][Full Text] [Related]
7. Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema.
Messenger WB; Beardsley RM; Flaxel CJ
Drug Des Devel Ther; 2013; 7():425-34. PubMed ID: 23737661
[TBL] [Abstract][Full Text] [Related]
8. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
9. Economic evaluation of a fluocinolone acetonide intravitreal implant for patients with DME based on the FAME study.
Cutino A; Green K; Kendall R; Moore PT; Zachary C
Am J Manag Care; 2015 Jan; 21(4 Suppl):S63-72. PubMed ID: 25734663
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies.
Pochopien M; Beiderbeck A; McEwan P; Zur R; Toumi M; Aballéa S
BMC Health Serv Res; 2019 Jan; 19(1):22. PubMed ID: 30626376
[TBL] [Abstract][Full Text] [Related]
12. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
[TBL] [Abstract][Full Text] [Related]
13. Fluocinolone Acetonide Intravitreal Implant 0.19 mg (ILUVIEN
Syed YY
Drugs; 2017 Apr; 77(5):575-583. PubMed ID: 28283896
[TBL] [Abstract][Full Text] [Related]
14. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial.
Pearson PA; Comstock TL; Ip M; Callanan D; Morse LS; Ashton P; Levy B; Mann ES; Eliott D
Ophthalmology; 2011 Aug; 118(8):1580-7. PubMed ID: 21813090
[TBL] [Abstract][Full Text] [Related]
15. Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant.
Ciulla TA; Harris A; McIntyre N; Jonescu-Cuypers C
Expert Opin Pharmacother; 2014 May; 15(7):953-9. PubMed ID: 24661081
[TBL] [Abstract][Full Text] [Related]
16. Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema.
Puliafito CA; Cousins SW; Bacharach J; Gonzalez VH; Holekamp NM; Merrill PT; Ohr MP; Parrish RK; Riemann CD
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4 Suppl):S4-S15. PubMed ID: 27096289
[TBL] [Abstract][Full Text] [Related]
17. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
[TBL] [Abstract][Full Text] [Related]
18. Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema.
Holden SE; Currie CJ; Owens DR
Curr Med Res Opin; 2017 Oct; 33(sup2):45-52. PubMed ID: 28881146
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroid use for diabetic macular edema: old fad or new trend?
Stewart MW
Curr Diab Rep; 2012 Aug; 12(4):364-75. PubMed ID: 22581206
[TBL] [Abstract][Full Text] [Related]
20. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
